AVIR - Atea Pharmaceuticals, Inc.
After hours:
| Previous close | 4.6300 |
| Open | 4.6050 |
| Bid | 4.5500 x 1200 |
| Ask | 4.8600 x 1800 |
| Day's range | 4.5300 - 4.7100 |
| 52-week range | 2.9400 - 9.7900 |
| Volume | |
| Avg. volume | 780,030 |
| Market cap | 390.309M |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2600 |
| Earnings date | 07 Aug 2023 - 11 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
Simply Wall St.Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is a favorite amongst institutional investors who own 62%
Every investor in Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) should be aware of the most powerful shareholder groups...
- Simply Wall St.
Atea Pharmaceuticals (NASDAQ:AVIR) shareholders have endured a 42% loss from investing in the stock a year ago
The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that...
ZacksAtea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade
Atea Pharmaceuticals, Inc. (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ZacksAfter Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR)
The heavy selling pressure might have exhausted for Atea Pharmaceuticals, Inc. (AVIR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ZacksWhy Atea Pharmaceuticals (AVIR) Might Surprise This Earnings Season
Atea Pharmaceuticals (AVIR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ZacksNovo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates
Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
- Simply Wall St.
One Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) insider upped their stake by 106% in the previous year
Looking at Atea Pharmaceuticals, Inc.'s ( NASDAQ:AVIR ) insider transactions over the last year, we can see that...
ZacksAtea (AVIR) Dengue Candidate Gets Fast Track Designation
Atea Pharmaceuticals (AVIR) obtains Fast Track Designation in the United States for AT-752 for the treatment of dengue virus infection.
- Simply Wall St.
With 62% ownership of the shares, Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is heavily dominated by institutional owners
If you want to know who really controls Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ), then you'll have to look at the...
Motley FoolAtea Pharmaceuticals, Inc. (AVIR) Q2 2022 Earnings Call Transcript
With me today from Atea are chief executive officer and founder, Dr. Before we begin the call, as outlined on Slide 2, I would like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties.
ZacksAtea Pharmaceuticals, Inc. (AVIR) Upgraded to Strong Buy: What Does It Mean for the Stock?
Atea Pharmaceuticals, Inc. (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- Simply Wall St.
Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Most readers would already be aware that Atea Pharmaceuticals' (NASDAQ:AVIR) stock increased significantly by 11% over...
- Motley Fool
Use This 1 Genius Trick for Finding Dirt Cheap Biotech Stocks in the Bear Market
The bear market is slamming biotech stocks as hard as any. Shares of the industry-tracking SPDR S&P Biotech ETF (NYSEMKT: XBI) are down by more than 33% so far this year, and its five-year total return is just below breakeven thanks to its dramatic collapse in 2021. With sentiment about biotech so persistently bad, bargain-hunting investors should be on the prowl, as there are bound to be a few diamonds in the rough out there.
- Simply Wall St.
Atea Pharmaceuticals (NASDAQ:AVIR) shareholders have endured a 68% loss from investing in the stock a year ago
It is doubtless a positive to see that the Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) share price has gained some 33...